Show simple item record

dc.contributor.authorBertomeu-González, Vicente
dc.contributor.authorAnguita, Manuel
dc.contributor.authorMoreno-Arribas, José
dc.contributor.authorCequier, Ángel
dc.contributor.authorMuñiz, Javier
dc.contributor.authorCastillo-Castillo, Jesús
dc.contributor.authorSanchis, Juan
dc.contributor.authorRoldán, Inmaculada
dc.contributor.authorMarín, Francisco
dc.contributor.authorBertomeu-Martínez, Vicente
dc.date.accessioned2015-08-24T11:06:25Z
dc.date.issued2015-05-11
dc.identifier.citationBertomeu-González V, Anguita M, Moreno-Arribas J. Quality of anticoagulation with vitamin K antagonists. Clin Cardiol. 2015;38(6):357-364es_ES
dc.identifier.urihttp://hdl.handle.net/2183/14875
dc.description.abstract[Abstract] Background. Vitamin K antagonists (VKA) have a narrow therapeutic range, and literature analysis reveals poor quality of anticoagulation control. We sought to assess the prevalence of poor anticoagulant control in patients under VKA treatment in the prevention of stroke for atrial fibrillation (AF). Hypothesis.Control of anticoagulation with VKA is inadequate in a high percentage of patients with AF. Methods.Patients with AF under VKA treatment were prospectively recruited in this observational registry. The sample comprised 948 patients. The estimated time spent in the therapeutic range (TTR) was calculated, and variables related with a TTR >65% were analyzed. Results.Mean age was 73.8 ± 9.4 years, and 42.5% of the patients were women. Mean TTR was 63.77% ± 23.80% for the direct method and 60.27% ± 24.48% for the Rosendaal method. Prevalence of poor anticoagulation control was 54%. Variables associated with good anticoagulation control were university studies (odds ratio [OR]: 1.99, 95% confidence interval [CI]: 1.08-3.64), chronic hepatic disease (OR: 8.15, 95% CI: 1.57-42.24), low comorbidity expressed as Charlson index (OR: 0.87, 95% CI: 0.76-0.99), no previous cardiac disease (OR: 0.64, 95% CI: 0.41-0.98), lower risk of bleeding assessed as hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly age, and use of drugs or alcohol (HAS-BLED; OR: 0.81, 95% CI: 0.69-0.95), and lower heart rate (OR: 0.99, 95% CI: 0.98-0.99). Conclusions.Patients who receive VKA to prevent stroke for AF spend less than half the time within therapeutic range.es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; RD12/0042/0068es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; RD12/0042/0010
dc.description.sponsorshipInstituto de Salud Carlos III; RD12/0042/0069
dc.description.sponsorshipInstituto de Salud Carlos III; RD12/0042/0049
dc.description.sponsorshipInstituto de Salud Carlos III; RD12/0042/0063
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.relation.urihttp://dx.doi.org/10.1002/clc.22397es_ES
dc.rightsThis is the peer reviewed version of article which has been published in final form at Wiley Online Library. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving.es_ES
dc.titleQuality of anticoagulation with vitamin K antagonistses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
dc.date.embargoEndDate2016-05-11es_ES
dc.date.embargoLift2016-05-11


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record